Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Receptos reports third quarter 2013 financial results
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Spin-offs: Meet the structure specialists
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Drug Safety Labeling Changes
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Patient reported outcome measures in neurogenic bladder.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Pages